Yuyu Pharma, Inc. (KRX:000220)
South Korea
· Delayed Price · Currency is KRW 4,230.00
+30.00 (0.71%)
Mar 10, 2026, 1:34 PM KST
Yuyu Pharma Revenue
Yuyu Pharma had revenue of 37.79B KRW in the quarter ending September 30, 2025, with 12.48% growth. This brings the company's revenue in the last twelve months to 139.51B, up 3.50% year-over-year. In the year 2024, Yuyu Pharma had annual revenue of 133.15B, down -2.96%.
Revenue (ttm)
139.51B
Revenue Growth
+3.50%
P/S Ratio
0.47
Revenue / Employee
549.26M
Employees
254
Market Cap
66.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 133.15B | -4.06B | -2.96% |
| Dec 31, 2023 | 137.21B | -1.67B | -1.20% |
| Dec 31, 2022 | 138.88B | 23.23B | 20.08% |
| Dec 31, 2021 | 115.66B | 17.54B | 17.87% |
| Dec 31, 2020 | 98.12B | 7.24B | 7.97% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MYUNGMOON Pharm co.,Ltd | 193.64B |
| Aprogen Biologics | 74.91B |
| Enzychem Lifesciences | 72.17B |
| Kukje Pharma | 173.80B |
| CKD Bio | 159.93B |
| Ildong Holdings | 620.44B |
| Kyongbo Pharmaceutical | 252.20B |
| Jeil Pharma Holdings | 707.15B |